Cargando…
Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
Coronavirus disease 2019 (COVID-19) is a fatal infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The virus infection is initiated upon recognition and binding of the spike (S) protein receptor-binding domain (RBD) to the host cell surface receptor, angiotensi...
Autores principales: | Gurung, Arun Bahadur, Ali, Mohammad Ajmal, Lee, Joongku, Farah, Mohammad Abul, Al-Anazi, Khalid Mashay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752028/ https://www.ncbi.nlm.nih.gov/pubmed/33493919 http://dx.doi.org/10.1016/j.jiph.2020.12.014 |
Ejemplares similares
-
Structural and functional insights into the major mutations of SARS-CoV-2 Spike RBD and its interaction with human ACE2 receptor
por: Gurung, Arun Bahadur, et al.
Publicado: (2022) -
The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp
por: Gurung, Arun Bahadur, et al.
Publicado: (2021) -
Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach
por: Gurung, Arun Bahadur, et al.
Publicado: (2020) -
In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
por: Gurung, Arun Bahadur, et al.
Publicado: (2020) -
Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme
por: Bahadur Gurung, Arun, et al.
Publicado: (2020)